EP4094779A4 - ACTIVE CONJUGATE OF ERIBULIN DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN MEDICINE - Google Patents
ACTIVE CONJUGATE OF ERIBULIN DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN MEDICINE Download PDFInfo
- Publication number
- EP4094779A4 EP4094779A4 EP21744595.6A EP21744595A EP4094779A4 EP 4094779 A4 EP4094779 A4 EP 4094779A4 EP 21744595 A EP21744595 A EP 21744595A EP 4094779 A4 EP4094779 A4 EP 4094779A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- eribulin
- medicine
- derivative
- preparation
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title 2
- 229940079593 drug Drugs 0.000 title 1
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical class C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010073671 | 2020-01-22 | ||
CN202010114980 | 2020-02-25 | ||
CN202011153368 | 2020-10-26 | ||
PCT/CN2021/073314 WO2021148003A1 (zh) | 2020-01-22 | 2021-01-22 | 艾日布林衍生物的药物偶联物、其制备方法及其在医药上的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP4094779A1 EP4094779A1 (en) | 2022-11-30 |
EP4094779A4 true EP4094779A4 (en) | 2023-11-22 |
Family
ID=76992064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP21744595.6A Pending EP4094779A4 (en) | 2020-01-22 | 2021-01-22 | ACTIVE CONJUGATE OF ERIBULIN DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN MEDICINE |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230144203A1 (pt) |
EP (1) | EP4094779A4 (pt) |
JP (1) | JP2023511163A (pt) |
KR (1) | KR20220130160A (pt) |
CN (1) | CN114845739A (pt) |
AU (1) | AU2021210079A1 (pt) |
BR (1) | BR112022014398A2 (pt) |
CA (1) | CA3168654A1 (pt) |
MX (1) | MX2022009044A (pt) |
TW (1) | TW202140078A (pt) |
WO (1) | WO2021148003A1 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4055053A1 (en) | 2019-11-07 | 2022-09-14 | Eisai R&D Management Co., Ltd. | Anti-mesothelin eribulin antibody-drug conjugates and methods of use |
CN117881431A (zh) * | 2021-08-24 | 2024-04-12 | 昆山新蕴达生物科技有限公司 | 一种由可断裂连接子偶联的抗体偶联药物 |
CN117677400A (zh) * | 2021-09-16 | 2024-03-08 | 正大天晴药业集团股份有限公司 | 抗her3抗体药物偶联物及其组合物和用途 |
TW202317088A (zh) * | 2021-10-14 | 2023-05-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 艾日布林衍生物的製備方法 |
WO2023098691A1 (zh) * | 2021-12-01 | 2023-06-08 | 上海生物制品研究所有限责任公司 | 抗体药物偶联物及其用途 |
WO2023103854A1 (zh) * | 2021-12-09 | 2023-06-15 | 昆山新蕴达生物科技有限公司 | 一种亲和力改善的抗体-药物偶联物、其制备方法及应用 |
WO2023124963A1 (zh) * | 2021-12-27 | 2023-07-06 | 昆山新蕴达生物科技有限公司 | 一种可逆反应减少的抗体-药物偶联物,其制备方法及应用 |
TW202334207A (zh) * | 2022-01-26 | 2023-09-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含抗cd79b抗體藥物偶聯物的醫藥組成物及其用途 |
WO2023143319A1 (zh) * | 2022-01-28 | 2023-08-03 | 启德医药科技(苏州)有限公司 | 抗体药物偶联物、药物组合物及用途 |
WO2023143320A1 (zh) * | 2022-01-28 | 2023-08-03 | 博瑞生物医药(苏州)股份有限公司 | 用于制备抗体药物偶联物的连接子、化合物及用途 |
TW202340252A (zh) * | 2022-01-29 | 2023-10-16 | 大陸商上海盛迪醫藥有限公司 | 糖皮質激素的藥物偶聯物 |
WO2023155808A1 (zh) * | 2022-02-16 | 2023-08-24 | 苏州宜联生物医药有限公司 | 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途 |
WO2024078612A1 (en) * | 2022-10-14 | 2024-04-18 | Genequantum Healthcare (Suzhou) Co., Ltd. | Linker-payload compound, conjugates and applications thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110475A2 (en) * | 2004-05-10 | 2005-11-24 | Abgenomics Corporation | Antibodies |
EP2639243A1 (en) * | 2010-11-10 | 2013-09-18 | Nippon Kayaku Kabushiki Kaisha | Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same |
WO2014011519A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
WO2014011521A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti - cd79b antibodies |
WO2014011520A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
US20140294851A1 (en) * | 2013-04-01 | 2014-10-02 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
WO2017151979A1 (en) * | 2016-03-02 | 2017-09-08 | Eisai Inc. | Eribulin-based antibody-drug conjugates and methods of use |
WO2017214491A1 (en) * | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
CN107488230A (zh) * | 2017-09-01 | 2017-12-19 | 浙江大学 | 一种抗人CD79a胞外端蛋白的抗体、编码基因及应用 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US5079233A (en) | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
PT1087960E (pt) * | 1998-06-17 | 2011-06-17 | Eisai R&D Man Co Ltd | Análogos macrocíclicos e métodos de sua utilização e preparação |
US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
CN100360567C (zh) | 2002-03-01 | 2008-01-09 | 免疫医疗公司 | Rs7抗体 |
EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
US8257706B2 (en) | 2006-08-25 | 2012-09-04 | Seattle Genetics, Inc. | CD30 binding agents and uses thereof |
SI2247620T1 (sl) * | 2008-01-31 | 2016-09-30 | Genentech, Inc. | Protitelesa proti CD79b in imunokonjugati in postopki za uporabo |
EP3184512B1 (en) | 2012-01-13 | 2020-12-23 | The General Hospital Corporation | Anesthetic compounds and related methods of use |
EP3632471A1 (en) | 2012-10-11 | 2020-04-08 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
SG11201704449VA (en) * | 2014-12-05 | 2017-06-29 | Genentech Inc | ANTI-CD79b ANTIBODIES AND METHODS OF USE |
WO2018217894A1 (en) * | 2017-05-24 | 2018-11-29 | Eisai R&D Management Co., Ltd. | Fluorine-labelled halichondrin derivatives and related methods of synthesis |
KR20200099123A (ko) * | 2017-12-15 | 2020-08-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 생체활성 접합체, 이의 제조 방법 및 용도 |
BR112021004656A2 (pt) | 2018-09-26 | 2021-06-01 | Jiangsu Hengrui Medicine Co., Ltd. | conjugado fármaco-ligante de análogo exatecano, método para preparar o mesmo e aplicação do mesmo |
-
2021
- 2021-01-22 MX MX2022009044A patent/MX2022009044A/es unknown
- 2021-01-22 BR BR112022014398A patent/BR112022014398A2/pt unknown
- 2021-01-22 WO PCT/CN2021/073314 patent/WO2021148003A1/zh active Application Filing
- 2021-01-22 TW TW110102507A patent/TW202140078A/zh unknown
- 2021-01-22 AU AU2021210079A patent/AU2021210079A1/en active Pending
- 2021-01-22 KR KR1020227027736A patent/KR20220130160A/ko unknown
- 2021-01-22 JP JP2022544350A patent/JP2023511163A/ja active Pending
- 2021-01-22 CA CA3168654A patent/CA3168654A1/en active Pending
- 2021-01-22 CN CN202180007579.2A patent/CN114845739A/zh active Pending
- 2021-01-22 US US17/794,732 patent/US20230144203A1/en active Pending
- 2021-01-22 EP EP21744595.6A patent/EP4094779A4/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110475A2 (en) * | 2004-05-10 | 2005-11-24 | Abgenomics Corporation | Antibodies |
EP2639243A1 (en) * | 2010-11-10 | 2013-09-18 | Nippon Kayaku Kabushiki Kaisha | Anti single-strand type-iv collagen polypeptide antibody, and pharmaceutical, or agent for diagnosing, preventing or treating tumours, containing same |
WO2014011519A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd79b antibodies |
WO2014011521A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti - cd79b antibodies |
WO2014011520A1 (en) * | 2012-07-09 | 2014-01-16 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
US20140294851A1 (en) * | 2013-04-01 | 2014-10-02 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
WO2017151979A1 (en) * | 2016-03-02 | 2017-09-08 | Eisai Inc. | Eribulin-based antibody-drug conjugates and methods of use |
WO2017214491A1 (en) * | 2016-06-09 | 2017-12-14 | Blinkbio, Inc. | Silanol based therapeutic payloads |
CN107488230A (zh) * | 2017-09-01 | 2017-12-19 | 浙江大学 | 一种抗人CD79a胞外端蛋白的抗体、编码基因及应用 |
Non-Patent Citations (5)
Title |
---|
CAROLINE MIGNARD ET AL.: "Abstract 1770: Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors", CANCER RESEARCH, vol. 78, no. 13_supplement, 1 July 2018 (2018-07-01), XP093062249, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/78/13_Supplement/1770/626150/Abstract-1770-Morab-202-a-folate-receptor-alpha> [retrieved on 20230710], DOI: 10.1158/1538-7445.AM2018-1770 * |
MIGNARD C. ET AL: "Morab-202, a folate receptor alpha-targeted antibody-drug conjugate, shows a highly potent activity against a panel of FRA-expressing tumors", #1770, 1 July 2018 (2018-07-01), XP093062251, Retrieved from the Internet <URL:https://www.oncodesign.com/wp-content/uploads/2021/07/ONCODESIGN_AACR_2018_-_MORAB-202_A_FOLATE_RECEPTOR_ALPHA-TARGETED_ANTIBODY-.pdf> [retrieved on 20230710] * |
See also references of WO2021148003A1 * |
SRIDHAR NARAYAN ET AL: "Novel second generation analogs of eribulin. Part III: Bloodbrain barrier permeability and in vivo activity in a brain tumor model", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 21, no. 6, 20 January 2011 (2011-01-20), pages 1639 - 1643, XP028169544, ISSN: 0960-894X, [retrieved on 20110126], DOI: 10.1016/J.BMCL.2011.01.096 * |
VELANI ARPITA ET AL: "Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody-Drug Conjugates (ADCs)", CYTOTOXIC PAYLOADS FOR ANTIBODY-DRUG CONJUGATES, 2019, pages 117 - 136, XP009548568, ISBN: 978-1-78801-077-1 * |
Also Published As
Publication number | Publication date |
---|---|
CN114845739A (zh) | 2022-08-02 |
JP2023511163A (ja) | 2023-03-16 |
BR112022014398A2 (pt) | 2022-09-13 |
TW202140078A (zh) | 2021-11-01 |
MX2022009044A (es) | 2022-08-11 |
WO2021148003A1 (zh) | 2021-07-29 |
EP4094779A1 (en) | 2022-11-30 |
CA3168654A1 (en) | 2021-07-29 |
US20230144203A1 (en) | 2023-05-11 |
AU2021210079A1 (en) | 2022-08-25 |
KR20220130160A (ko) | 2022-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP4094779A4 (en) | ACTIVE CONJUGATE OF ERIBULIN DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN MEDICINE | |
EP4129345A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIBODY-DRUG CONJUGATE AND USE THEREOF | |
WO2004071529A3 (en) | Uses of anti-insulin-like growth factor i receptor antibodies | |
MX2023001163A (es) | Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo. | |
EP3858840A4 (en) | INDOL MACROCYCLIC DERIVATIVE, METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE | |
EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
EP4116302A4 (en) | COMPOUND AND METHOD OF PRODUCTION THEREOF AND APPLICATION THEREOF IN THE PRODUCTION OF A THERAPEUTIC ANTICANCER DRUG | |
EP3950690A4 (en) | PYRROLOHETEROCYCLIC DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE | |
EP3954380A4 (en) | SELF-EMULSIFYING FLAVONOID-POLYPHENOL MEDICINAL COMPOSITION, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITION AND ITS USE | |
EP4101860A4 (en) | HYALURONIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND HYALURONIC ACID DERIVATIVES-INGREDIENT CONJUGATE | |
EP3995496A4 (en) | CAMPTOTHECIN MEDICINE AND AN ANTIBODY CONJUGATE THEREOF | |
EP4005581A4 (en) | HYPERICUM JAPONICUM THUNB EXTRACT. AND ITS APPLICATION IN THE PREPARATION OF A NEW MEDICINE AGAINST CORONAVIRUS | |
EP4159203A4 (en) | SUSTAINED-RELEASE ORAL COMPOSITION FOR AN INSOLUBLE DRUG, AND PREPARATION METHOD THEREFOR | |
EP4089094A4 (en) | TRICYCLIC TETRAHYDROISOCHINOLINE DERIVATIVE, PROCESS FOR PRODUCTION THEREOF AND APPLICATION THEREOF IN MEDICINE | |
EP4089084A4 (en) | CANNABIDIOL DERIVATIVE AND ITS PREPARATION METHOD AND ITS MEDICAL USE | |
EP3907223A4 (en) | PROCESS FOR PRODUCTION OF DRUG TOXIN PNU-159682 AN ANTIBODY DRUG CONJUGATE AND INTERMEDIATE THEREOF | |
EP3907234A4 (en) | PROCESS FOR THE PREPARATION AND INTERMEDIATE OF A DRUG LINKER FOR AN ANTIBODY-DRUG CONJUGATE MC-MMAF | |
WO2009001209A8 (en) | Use of conjugates of hyaluronic acid in the local treatment of hyperproliferative skin diseases | |
WO2006131651A3 (fr) | Composition a base d'une avermectine et d’ηydrocortisone notamment pour le traitement de la rosacée | |
EP3586843A4 (en) | GLUCOCALYXIN A DERIVATIVE, PHARMACEUTICAL SALT THEREOF, OR PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF IN THE MANUFACTURING OF MEDICINAL PRODUCTS FOR THE TREATMENT OF PSORIASIS | |
EP4140495A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER COMPRISING A FUSION PROTEIN COMPRISING AN IL-2 PROTEIN AND A CD80 PROTEIN AND AN ANTI-CANCER DRUG | |
EP4053151A4 (en) | KERATIN BD-1, PREPARATION METHOD, AS WELL AS PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
EP4101466A4 (en) | HYALURONIC ACID DERIVATIVE COMPOSITION, PHARMACEUTICAL COMPOSITION AND HYALURONIC ACID DERIVATIVE-ACTIVE CONJUGATE COMPOSITION | |
AU2021386252A9 (en) | Combinations of small molecule drug conjugate and car-expressing cytotoxic lymphocytes and methods of treating cancer using the same | |
EP4005572A4 (en) | BENZAMIDE DERIVATIVE, METHOD FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS AN ACTIVE SUBSTANCE FOR THE PREVENTION OR TREATMENT OF CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220808 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20231023 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20231017BHEP Ipc: C07K 16/28 20060101ALI20231017BHEP Ipc: C07D 307/20 20060101ALI20231017BHEP Ipc: A61K 47/68 20170101AFI20231017BHEP |